The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

A potential $4 billion licensing deal with Vor Bio triggered a slide in RemeGen's stock price. Otsuka obtained a BCMAXCD3 ...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat ...

Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...

The lung-cancer drug Datroway, being jointly developed by AstraZeneca and Daiichi Sankyo, has been approved in the U.S. to treat adult patients with non-small cell lung cancer. "AstraZeneca's Datroway ...

AstraZeneca and Daiichi Sankyo’s Datroway drug has been approved in the U.S. to treat adult patients with non-small cell lung cancer. British pharmaceutical company AstraZeneca said Tuesday that ...